These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315 [TBL] [Abstract][Full Text] [Related]
3. Class I Phosphoinositide 3-Kinase Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563 [TBL] [Abstract][Full Text] [Related]
4. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485 [TBL] [Abstract][Full Text] [Related]
5. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989 [TBL] [Abstract][Full Text] [Related]
6. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804 [TBL] [Abstract][Full Text] [Related]
7. p110α and p110β isoforms of PI3K are involved in protection against H Singh P; Bano N; Hossain MM; Basit R; Dar MJ Breast Cancer; 2019 May; 26(3):378-385. PubMed ID: 30499025 [TBL] [Abstract][Full Text] [Related]
8. PIK3CB/p110β is a selective survival factor for glioblastoma. Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844 [TBL] [Abstract][Full Text] [Related]
9. Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. Mazloumi Gavgani F; Karlsson T; Tangen IL; Morovicz AP; Arnesen VS; Turcu DC; Ninzima S; Spang K; Krakstad C; Guillermet-Guibert J; Lewis AE J Cell Sci; 2021 Feb; 134(3):. PubMed ID: 33536247 [TBL] [Abstract][Full Text] [Related]
10. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Crowder RJ; Phommaly C; Tao Y; Hoog J; Luo J; Perou CM; Parker JS; Miller MA; Huntsman DG; Lin L; Snider J; Davies SR; Olson JA; Watson MA; Saporita A; Weber JD; Ellis MJ Cancer Res; 2009 May; 69(9):3955-62. PubMed ID: 19366795 [TBL] [Abstract][Full Text] [Related]
11. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Dbouk HA; Pang H; Fiser A; Backer JM Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680 [TBL] [Abstract][Full Text] [Related]
12. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. Kim K; Lee HW Appl Immunohistochem Mol Morphol; 2018; 26(10):740-748. PubMed ID: 28549032 [TBL] [Abstract][Full Text] [Related]
13. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431 [TBL] [Abstract][Full Text] [Related]
14. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Jia S; Liu Z; Zhang S; Liu P; Zhang L; Lee SH; Zhang J; Signoretti S; Loda M; Roberts TM; Zhao JJ Nature; 2008 Aug; 454(7205):776-9. PubMed ID: 18594509 [TBL] [Abstract][Full Text] [Related]
15. PTEN-deficient cancers depend on PIK3CB. Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318 [TBL] [Abstract][Full Text] [Related]
17. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Yip SC; El-Sibai M; Hill KM; Wu H; Fu Z; Condeelis JS; Backer JM Cell Motil Cytoskeleton; 2004 Nov; 59(3):180-8. PubMed ID: 15468162 [TBL] [Abstract][Full Text] [Related]
18. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061 [TBL] [Abstract][Full Text] [Related]
19. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009 [TBL] [Abstract][Full Text] [Related]
20. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. Juvin V; Malek M; Anderson KE; Dion C; Chessa T; Lecureuil C; Ferguson GJ; Cosulich S; Hawkins PT; Stephens LR PLoS One; 2013; 8(10):e75045. PubMed ID: 24124465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]